WithdrawnPhase 2NCT00992693

Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities

Studying Crimean-Congo hemorrhagic fever

Last synced from ClinicalTrials.gov May 12, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: U.S. Army Medical Research and Development Command
Principal Investigator: Elizabeth Rini, MD
Landstuhl Regional Medical Center, Germany
Intervention: Ribavirin (Virazole) Injection(drug)
Eligibility: 17-65 years · All sexes
Timeline: 2009 – 2019

Study locations (1)

Landstuhl Regional Medical Center, Landstuhl, Rhineland-Palatinate, Germany

Collaborators

Bausch Health Americas, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00992693 on ClinicalTrials.gov

Other trials for Crimean-Congo hemorrhagic fever

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE1NCT06799013
Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever
HDT Bio

See all trials for Crimean-Congo hemorrhagic fever →

← Back to all trials